{
    "name": "miglustat",
    "comment": "Rx",
    "other_names": [
        "Zavesca"
    ],
    "classes": [
        "Enzyme Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/zavesca-miglustat-342874",
    "pregnancy": {
        "common": [
            "Based on findings from animal reproduction studies, drug may cause fetal harm when administered to a pregnant woman; available data from postmarketing case reports with drug use in pregnancy are insufficient to assess a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes; there are risks associated with symptomatic Type I Gaucher disease in pregnancy, including hepatosplenomegaly and thrombocytopenia; advise pregnant women of potential risks to the fetus",
            "Pregnancy may exacerbate existing Type 1 Gaucher disease symptoms or result in new disease manifestations; Type 1 Gaucher disease manifestations may lead to adverse pregnancy outcomes including, hepatosplenomegaly which can interfere with the normal growth of a pregnancy and thrombocytopenia which can lead to increased bleeding and possible hemorrhage"
        ],
        "specific": [
            {
                "type": "Reproductive potential",
                "description": [
                    "Findings from a small clinical study in seven healthy adult males who received therapy for six weeks did not indicate effects on male fertility; studies in male rats have shown that drug decreased fertility but findings were reversible; studies in female rats have shown increased post-implantation loss and decreased embryo-fetal survival"
                ]
            },
            {
                "type": "Animal data",
                "description": [
                    "In animal reproduction studies, drug was maternally toxic in rabbits at exposures near the expected human therapeutic dose and caused embryo-fetal toxicities in rats at doses twice recommended human dose; no adverse developmental outcomes were observed with administration of drug to pregnant rats at dose levels 6 times recommended human dose"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no available data on presence of drug in either human or animal milk, effects on breastfed infant, or on milk production; based on physical properties of miglustat, drug is likely to be present in breast milk; because of potential for serious adverse reactions in breastfed infants, advise women that breastfeeding is not recommended"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to product or components"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Cases of peripheral neuropathy have been reported; patients should undergo baseline & repeat neuro evaluation at 6 month intervals; consider treatment cessation if symptoms develop",
                "Tremor may develop or be exacerbated; dose reduction may ameliorate, usually within days; discontinuation may be required",
                "Avoid high carbohydrate foods during treatment to lessen side effect of diarrhea; weight loss reported due to the diarrhea; incidence decreases over time",
                "May affect spermatogenesis & sperm parameters; male patients should use reliable contraception",
                "May increase clearance of Cerezyme (imiglucerase); concomitant use not recommended",
                "MIld decrease in platelet counts reported; bleeding not reported",
                "Exacerbation of existing tremor may occur that may resolve over time or improve with dose reduction; may consider discontinuing therapy if it does not resolve"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "imiglucerase",
            "description": {
                "common": "miglustat decreases levels of imiglucerase by increasing renal clearance. Use Caution/Monitor. Effects on imiglucerase levels variable; concomitant use not recommended by mfr of miglustat (Zavesca)."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Diarrhea",
            "percent": "89-100"
        },
        {
            "name": "Weight loss",
            "percent": "66-70"
        },
        {
            "name": "Abdominal pain",
            "percent": "18-67"
        },
        {
            "name": "Flatulence",
            "percent": "29-50"
        },
        {
            "name": "Dizziness",
            "percent": "11"
        },
        {
            "name": "Headache",
            "percent": "21-22"
        },
        {
            "name": "Tremor",
            "percent": "11-30"
        },
        {
            "name": "Nausea",
            "percent": "8-22"
        },
        {
            "name": "Vomiting",
            "percent": "4-11"
        },
        {
            "name": "Visual disturbances",
            "percent": "17"
        },
        {
            "name": "Thrombocytopenia",
            "percent": "6-10"
        },
        {
            "name": "Vomiting",
            "percent": "4"
        },
        {
            "name": "Memory impairment",
            "percent": "8"
        },
        {
            "name": "Migraine",
            "percent": "6"
        },
        {
            "name": "Abdominal distension",
            "percent": "8"
        },
        {
            "name": "Anorexia",
            "percent": "7"
        },
        {
            "name": "Epigastric pain",
            "percent": "6"
        },
        {
            "name": "Thrombocytopenia",
            "percent": "5-7"
        }
    ]
}